Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• CHK1 Ser/Thr kinase is a key regulator of the DNA damage response and normal cell cycle progression.
• Mutated FLT3-ITD tyrosine kinase receptor is implicated in acute myeloid leukemia (AML) pathogenesis.
• Understanding CHK1's role in FLT3-ITD-driven AML is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of CHK1 in the proliferation of acute myeloid leukemia cells expressing mutated FLT3-ITD.
• To evaluate the therapeutic potential of targeting CHK1 in FLT3-ITD-positive AML.

Main Methods:

• Pharmacological inhibition and shRNA-mediated downregulation of CHK1.
• Flow cytometry to analyze cell cycle progression.
• Lentiviral-mediated CHK1 overexpression and mutant expression (ser280).
• Cell viability and [3H] thymidine incorporation assays.
• Clonogenic growth assays with primary patient leukemic cells.

Main Results:

• Inhibition or downregulation of CHK1 reduced the proliferation rate of FLT3-ITD-expressing leukemic cell lines in a cytostatic manner.
• CHK1 inhibition did not cause accumulation in a specific cell cycle phase.
• CHK1 overexpression increased proliferation, while a ser280 mutant did not, indicating phosphorylation's importance.
• CHK1 inhibition reduced clonogenic growth of primary AML cells.
• Three out of four tested CHK1 inhibitors also potently inhibited the FLT3-ITD tyrosine kinase receptor.

Conclusions:

• CHK1 is identified as a critical regulator of proliferation in FLT3-ITD-positive leukemic cells.
• Targeting CHK1 presents a promising therapeutic strategy for FLT3-ITD-driven AML.
• The dual inhibitory effect of some compounds on both CHK1 and FLT3-ITD warrants further investigation.